ChemoCentryx (NASDAQ: CCXI) and Auxilium Pharmaceuticals (NASDAQ:AUXL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitabiliy.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ChemoCentryx and Auxilium Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChemoCentryx 0 1 2 0 2.67
Auxilium Pharmaceuticals 0 0 0 0 N/A

ChemoCentryx currently has a consensus target price of $11.00, indicating a potential upside of 5.87%. Given ChemoCentryx’s higher probable upside, equities analysts clearly believe ChemoCentryx is more favorable than Auxilium Pharmaceuticals.

Profitability

This table compares ChemoCentryx and Auxilium Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChemoCentryx N/A -58.48% -21.03%
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%

Valuation and Earnings

This table compares ChemoCentryx and Auxilium Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ChemoCentryx $20.17 million 24.81 -$31.34 million ($0.65) -15.98
Auxilium Pharmaceuticals N/A N/A N/A N/A N/A

Auxilium Pharmaceuticals has higher revenue, but lower earnings than ChemoCentryx.

Institutional and Insider Ownership

49.6% of ChemoCentryx shares are held by institutional investors. 26.8% of ChemoCentryx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

ChemoCentryx beats Auxilium Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

ChemoCentryx Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Auxilium Pharmaceuticals Company Profile

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.